PP76 Clinical Guidelines For Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis: Incorporating Rituximab To Enhance Equity In Access And Treatment In Brazil
Aline Rocha, Nitza Ferreira Muniz, Ana Carolina Pereira Nunes Pinto, Álvaro Atallah · 2025
Read PP76 Clinical Guidelines For Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis: Incorporating Rituximab To Enhance Equity In Access And Treatment In Brazil by Aline Rocha, Nitza Ferreira Muniz, Ana Carolina Pereira Nunes Pinto, Álvaro Atallah (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768726.txt.
Description
Aline Rocha and co-authors report a 2025 case study on how Brazil wrote care guidelines for a rare disease. The disease, called ANCA-associated vasculitis, attacks small blood vessels. It is uncommon but can kill. Brazil had to decide whether its public health system should pay for a drug called rituximab to treat it. A first review weighed the drug's benefits and costs against the standard drug already in use.
The first advice was against adding the drug. Then the plan went out for public comment. Patients and caregivers all spoke in favor. Technical comments stressed the standard drug's harms and its failure in a quarter of patients. New cost work also improved the drug's value picture. These steps helped reverse the first call, the authors report, and they present the case as a model for fair, open guideline work.
Catalog record
| CREATOR | Aline Rocha, Nitza Ferreira Muniz, Ana Carolina Pereira Nunes Pinto, Álvaro Atallah |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |